國立虎尾科技大學 |

Current applications for overcoming resistance to targeted therapies

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Current applications for overcoming resistance to targeted therapies/ edited by Myron R. Szewczuk, Bessi Qorri, Manpreet Sambi.
其他作者:	Szewczuk, Myron R.
出版者:	Cham :Springer International Publishing : : 2019.,
面頁冊數:	xviii, 320 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Drug targeting. -
電子資源:	https://doi.org/10.1007/978-3-030-21477-7
ISBN:	9783030214777

Current applications for overcoming resistance to targeted therapies
Current applications for overcoming resistance to targeted therapies[electronic resource] /edited by Myron R. Szewczuk, Bessi Qorri, Manpreet Sambi. - Cham :Springer International Publishing :2019. - xviii, 320 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.202196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Introduction to the Acquisition of Resistance to Targeted Therapy -- Targeting the Tumor Microenvironment to Overcome Resistance to Targeted Therapy -- Current Challenges and Applications of Oncolytic Viruses in Overcoming Resistance to Therapies in Cancer -- Novel Methods to Overcome Acquired Resistance to Immunotherapy -- Therapies to Overcome Multidrug-Resistant Receptors -- Overcoming Resistance to PARP Inhibition -- Novel Methods of Overcoming HER2 Therapy Resistance in Breast Cancer -- Emerging Novel Therapies for Overcoming Resistance to Targeted Therapies -- Targeting Epigenetic Regulators in Cancer to Overcome Resistance to Targeted Therapy -- Nanomedicine and Drug Delivery Systems in Overcoming Resistance to Targeted Therapy -- Index.

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

ISBN: 9783030214777

Standard No.: 10.1007/978-3-030-21477-7doiSubjects--Topical Terms:

581035
Drug targeting.

LC Class. No.: RM301.63 / .C877 2019

Dewey Class. No.: 615.7

Current applications for overcoming resistance to targeted therapies
LDR:02891nam a2200337 a 4500 001 941604
003 DE-He213
005 20191127135944.0
006 m d
007 cr nn 008maaau
008 200417s2019 gw s 0 eng d
020 $a 9783030214777 $q (electronic bk.)
020 $a 9783030214760 $q (paper)
024 7 $a 10.1007/978-3-030-21477-7 $2 doi
035 $a 978-3-030-21477-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.63 $b .C877 2019
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 615.7 $2 23
090 $a RM301.63 $b .C976 2019
245 0 0 $a Current applications for overcoming resistance to targeted therapies $h [electronic resource] / $c edited by Myron R. Szewczuk, Bessi Qorri, Manpreet Sambi.
260 $a Cham : $c 2019. $b Springer International Publishing : $b Imprint: Springer,
300 $a xviii, 320 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.20
505 0 $a Introduction to the Acquisition of Resistance to Targeted Therapy -- Targeting the Tumor Microenvironment to Overcome Resistance to Targeted Therapy -- Current Challenges and Applications of Oncolytic Viruses in Overcoming Resistance to Therapies in Cancer -- Novel Methods to Overcome Acquired Resistance to Immunotherapy -- Therapies to Overcome Multidrug-Resistant Receptors -- Overcoming Resistance to PARP Inhibition -- Novel Methods of Overcoming HER2 Therapy Resistance in Breast Cancer -- Emerging Novel Therapies for Overcoming Resistance to Targeted Therapies -- Targeting Epigenetic Regulators in Cancer to Overcome Resistance to Targeted Therapy -- Nanomedicine and Drug Delivery Systems in Overcoming Resistance to Targeted Therapy -- Index.
520 $a Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.
650 0 $a Drug targeting. $3 581035
650 0 $a Drug resistance in cancer cells. $3 681914
650 0 $a Lungs $x Cancer $x Treatment. $3 798534
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
700 1 $a Szewczuk, Myron R. $3 1228980
700 1 $a Qorri, Bessi. $3 1228981
700 1 $a Sambi, Manpreet. $3 1228982
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 1063064
856 4 0 $u https://doi.org/10.1007/978-3-030-21477-7
950 $a Biomedical and Life Sciences (Springer-11642)